Crispr Therapeutics shares tumble after significant earnings miss
Director Paul K. Yonamine of Central Pacific Financial Corp (NYSE:CPF) sold 2,765 shares of common stock on August 1, 2025, at a price of $26.25, totaling $72,581. The stock, currently trading at $26.14 with a market cap of $706 million, is fairly valued according to InvestingPro analysis.
The transaction was executed under a Rule 10b5-1 plan, which was established on March 5, 2025. This plan allows company insiders to set up a predetermined schedule for buying or selling company stock, providing a defense against potential accusations of insider trading. The company maintains a healthy 4.05% dividend yield and has consistently paid dividends for 13 consecutive years, demonstrating strong shareholder returns.
Following the sale, Yonamine directly owns 14,181 shares of Central Pacific Financial. He also indirectly owns 3,000 shares through the CPF Directors Deferred Compensation Plan. Additional holdings include 2,400 shares
In other recent news, Central Pacific Financial Corp. reported earnings for the second quarter of 2025 that exceeded market expectations. The company achieved an earnings per share (EPS) of $0.67, surpassing the forecasted $0.64. Additionally, Central Pacific Financial’s revenue reached $72.81 million, also beating the anticipated $71.8 million. These results highlight a positive performance for the company in the recent quarter. Despite the strong earnings and revenue figures, the stock price experienced a slight decline. However, the financial results may still be seen as a positive sign for investors. This news comes amidst broader market conditions affecting investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.